Examples of misconduct in clinical research include data fabrication, falsification of records, consent violations, and undisclosed protocol deviations — and when a sponsor or CRO suspects any of these mid-trial, reporting is not optional. Under the EU Clinical Trials Regulation, a “serious breach” must reach the competent authority within seven calendar days of discovery; US sponsors face a less prescriptive but equally binding duty to act “promptly” under 21 CFR 312.56. This article maps who a sponsor must notify, on what timeline, and how that notification interacts with a regulator’s decision to inspect.
Research misconduct in a clinical trial is the fabrication, falsification, or reckless misrepresentation of data or research conduct, distinct from good-faith error or a minor, adequately documented protocol deviation.
- What counts as misconduct in a clinical trial?
- When must a sponsor report suspected misconduct, and to whom?
- How does reporting interact with regulatory inspections?
- What happens after a sponsor reports suspected misconduct?
- Common questions about clinical research misconduct
- Implications for sponsors and CROs
What Counts as Misconduct in a Clinical Trial?
Clinical research misconduct is behaviour that deliberately or recklessly falls short of accepted standards for proposing, conducting, or reporting research. It is distinguished from an honest mistake or a single, well-documented deviation by intent, recklessness, or a repeated pattern.
Documented case categories from the US Office of Research Integrity (ORI) and academic reviews of clinical trial fraud include:
- Data fabrication — inventing patient visits, lab values, or entire case report forms that never occurred.
- Falsification — altering screening logs, backdating eligibility assessments, or changing test results to fit protocol windows.
- Consent violations — enrolling participants without valid informed consent, or forging consent documentation.
- Protocol violations — substituting one subject’s records for another’s, or conducting procedures without certified staff while reporting otherwise.
- Undisclosed conflicts of interest — financial or personal interests that bias trial design, conduct, or reporting.
- Failure to report adverse events — concealing or delaying safety data owed to an institutional review board (IRB) or ethics committee.
ORI’s published case summaries describe real findings including “falsely reporting to a data coordinating center that certain clinical trial staff… had done so, when they had not” and “creating records of interviews of subjects that were never performed.” These are not hypothetical categories — they are the recurring fact patterns behind actual PHS misconduct findings.
When Must a Sponsor Report Suspected Misconduct, and to Whom?
A sponsor’s reporting duty is triggered the moment it has credible grounds to suspect misconduct — not once an investigation has confirmed it. The recipient, deadline, and legal basis all depend on which regulatory regime governs the trial, and sponsors running multi-region studies must satisfy all of them in parallel.
| Jurisdiction | Trigger | Notify | Deadline | Legal basis |
|---|---|---|---|---|
| United States (IND-regulated drug/biologic trials) | Investigator non-compliance the sponsor cannot correct, or safety/data-integrity concerns forcing suspension | FDA and the reviewing IRB | Promptly — no fixed calendar-day rule, but expected without delay once the decision is made | 21 CFR 312.56(b)–(d) |
| United States (PHS/NIH-funded, non-IND research) | Suspected fabrication, falsification, or plagiarism (FFP) | Institutional research integrity officer, then the Office of Research Integrity | Per the institution’s own inquiry and investigation policy | 42 CFR Part 93 |
| European Union (trials under the Clinical Trials Regulation) | A “serious breach” likely to affect participant safety, rights, or data reliability | Concerned Member States via the Clinical Trials Information System (CTIS) | Without undue delay, no later than 7 calendar days of becoming aware | Regulation (EU) No 536/2014, Article 52 |
| United Kingdom | A “serious breach” of the protocol or the regulations | The Medicines and Healthcare products Regulatory Agency (MHRA) | Within 7 days of becoming aware | Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended), Regulation 29A |
Two consequences follow directly from this table. First, sponsors running the same trial across the US and EU cannot rely on a single reporting clock: the EU’s 7-day “serious breach” deadline is explicit and calendar-driven, while the FDA standard is outcome-driven and tied to specific triggering events such as investigator termination. Second, if the trial is PHS-funded, a sponsor’s obligations sit alongside — not instead of — the awardee institution’s separate duty under 42 CFR Part 93, which applies to the institution employing the researcher rather than to the commercial sponsor itself.
How Does Reporting Interact with Regulatory Inspections?
A misconduct report rarely closes the matter quietly — it frequently opens the door to a “for-cause” regulatory inspection. Regulators treat a sponsor’s own disclosure as both a compliance signal and a lead worth following up directly at the site.
In the US, the FDA’s Bioresearch Monitoring (BIMO) programme conducts for-cause inspections when a sponsor, IRB, or whistleblower flags data integrity concerns, independent of the routine, risk-based inspection schedule. In the EU and UK, a notified “serious breach” is a documented input into the GCP inspectorate’s risk assessment, and can trigger an unannounced inspection of the sponsor, CRO, or investigator site. Sponsors that self-report early and demonstrate a documented corrective action plan are generally viewed more favourably during inspection than those where a breach surfaces only through external whistleblowing or routine monitoring.
What Happens After a Sponsor Reports Suspected Misconduct?
Reporting is the start of a defined sequence, not the end of the sponsor’s obligation. Under 21 CFR 312.56, once a sponsor discovers an investigator is not complying with the signed investigator statement (FDA Form 1572), it must secure compliance or discontinue that investigator’s participation and shipment of investigational product, then notify the FDA of the termination.
- Sponsor performs an initial assessment and, where warranted, a root cause analysis of the suspected misconduct.
- Sponsor notifies the relevant regulator(s) and ethics committee/IRB within the applicable jurisdictional deadline.
- Sponsor implements corrective and preventive actions (CAPA), which may include investigator termination, site closure, or data exclusion.
- Where PHS funding is involved, the awardee institution runs its own inquiry/investigation under 42 CFR Part 93, independent of the sponsor’s regulatory notification.
- Findings are documented for the trial master file and made available to inspectors on request.
Common Questions About Clinical Research Misconduct
What are some examples of research misconduct?
The recurring examples in clinical trials are data fabrication, falsification of records or results, plagiarism in reporting, informed consent violations, and undisclosed conflicts of interest. ORI case summaries also document backdated visit records and fabricated subject interviews as recurring fact patterns in confirmed findings.
What are the five unethical practices most often cited in research?
Commonly cited categories are falsification of data, failure to credit others (plagiarism), conflicts of interest, and biased design or interpretation driven by outside influence, alongside fabrication. These sit on a spectrum with lesser “questionable research practices” that fall short of formal misconduct.
What are the three recognised types of research misconduct?
US federal policy defines research misconduct as fabrication, falsification, and plagiarism — often abbreviated FFP. This is the operative definition ORI applies under 42 CFR Part 93 when assessing PHS-funded research allegations.
What is clinical misconduct specifically?
Clinical misconduct is misconduct occurring within a trial’s conduct rather than its publication: consent breaches, fabricated case report forms, or falsified eligibility data. The UK Medical Research Council and Wellcome historically defined it as fabrication, falsification, plagiarism, or deception in proposing, conducting, or reporting research.
Implications for Sponsors and CROs
The practical takeaway for sponsors and CROs is that “report it eventually” is not a defensible standard in any jurisdiction. A written misconduct-escalation procedure needs a named responsible officer, a fixed internal assessment window shorter than the EU’s 7-day external deadline, and a clear map of which regulator, IRB, ethics committee, or funder must be notified for each trial in the portfolio. Institutions receiving PHS/NIH funding additionally need their own 42 CFR Part 93 assurance and inquiry procedure, run independently of the sponsor’s regulatory notifications.
As trials increasingly span the US, EU, and UK under a single protocol, the sponsors best placed to withstand scrutiny will be those who treat suspected misconduct as a multi-jurisdictional reporting event from the first credible signal, rather than a single notification to a single regulator. Research administration teams coordinating multi-site, multi-country trials are well positioned to own this escalation map, since they already sit at the interface between investigator sites, sponsors, and regulatory affairs.